In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”. As a founder and […]
Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize. The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in […]
Scailyte™ is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data.Over the past 3 years, we have established ScaiVision™, a proprietary data analytics platform for clinical research, which enables us to achieve groundbreaking discoveries in multiple disease areas. We have validated our approach by […]
At HEMEX, we regularly organize invitation-only pitch days, where selected startups get the opportunity to pitch in front of potential investors. The focus of our last 2019 pitch session was on startups seeking to revolutionize cancer diagnosis and treatment. Thank you Christina Vallgren, Marcus Palm, Martin Stauber, Seline Eisenring, Michael Krauthammer and Peter Nestorov for […]